Inovio Pharmaceuticals (INO) Set to Announce Earnings on Thursday

Inovio Pharmaceuticals (NASDAQ:INO - Get Free Report) is scheduled to post its quarterly earnings results after the market closes on Thursday, November 14th. Analysts expect Inovio Pharmaceuticals to post earnings of ($1.20) per share for the quarter. Parties interested in listening to the company's conference call can do so using this link.

Inovio Pharmaceuticals (NASDAQ:INO - Get Free Report) last announced its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($1.19) EPS for the quarter, missing the consensus estimate of ($1.10) by ($0.09). The firm had revenue of $0.10 million for the quarter, compared to the consensus estimate of $0.10 million. During the same quarter in the previous year, the company earned ($1.56) earnings per share. On average, analysts expect Inovio Pharmaceuticals to post $-5 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Inovio Pharmaceuticals Stock Performance

Shares of NASDAQ:INO traded down $0.15 during trading on Thursday, reaching $5.52. 299,781 shares of the company traded hands, compared to its average volume of 399,714. The company's 50 day moving average is $5.99 and its two-hundred day moving average is $8.44. Inovio Pharmaceuticals has a 52 week low of $3.89 and a 52 week high of $14.75.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on INO shares. HC Wainwright reaffirmed a "neutral" rating and issued a $15.00 price objective on shares of Inovio Pharmaceuticals in a research note on Monday, July 15th. Royal Bank of Canada reduced their price target on shares of Inovio Pharmaceuticals from $8.00 to $7.00 and set a "sector perform" rating on the stock in a research note on Friday, October 4th. Finally, Oppenheimer dropped their price objective on shares of Inovio Pharmaceuticals from $40.00 to $33.00 and set an "outperform" rating for the company in a research note on Monday, August 12th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, Inovio Pharmaceuticals presently has an average rating of "Hold" and an average target price of $43.80.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.